The proton pump inhibitor (PPI) heartburn medication Dexilant has been linked to long-term kidney damage, stomach cancer, and other serious side effects, a recent study suggests.
Free Confidential Lawsuit Evaluation: If you or a loved one has been injured by Dexilant, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against the manufacturer and our lawyers can help.
Update: Long-Term PPI Use Linked to Doubled Risk for Gastric Cancer
December 1, 2017 – Use of a proton-pump inhibitor like Dexilant after Helicobacter pylori eradication more than doubles your risk for stomach cancer, according to a new study published in the journal Gut.The researchers point out, however, that this was an observational study, which can’t prove cause and effect.
Dexilant (generic: dexlansoprazole) is used to treat stomach and esophagus problems such as gastroesophageal reflux disease (GERD). The drug works by decreasing the amount of acid the stomach produces, thereby relieving symptoms such as heartburn, difficulty swallowing and persistent cough. Dexlansoprazole was originally marketed under the trade name Kadipex, which was changed in March 2010 to avoid confusion with 2 other medications – Casodex and Kadian.
Heartburn Medications & Kidney Disease
People who use PPIs like Dexilant have a 20-50% increased risk of developing chronic kidney disease (CKD), according to a January 2016 study published in JAMA Internal Medicine. The study doesn’t confirm a direct cause-and-effect relationship between PPIs and CKD; however, according to the study’s authors, “We found there was an increasing risk associated with an increasing dose. That suggests that perhaps this observed effect is real.” Over time, chronic kidney disease can lead to kidney failure, requiring the patient to undergo regular dialysis and possibly a kidney transplant, according to the U.S. National Institutes of Health (NIH).
Kidney Disease Symptoms
- Weight loss / poor appetite
- Swollen ankles, feet or hands
- Shortness of breath
- Blood or protein in your urine
- Increased urination
- Itchy skin
- Muscle cramps
- High blood pressure (hypertension)
- Erectile dysfunction (ED)
According to new data from an ongoing Nurses’ Health Study, the side effects of Dexilant and other PPI drugs increase the risk of bone fractures, particularly among women who smoke. The study began focusing on bone fractures in 1982, and includes some 238,000 participants. Researchers found that women who smoke or used to smoke and regularly took a PPI had a 51% increased risk of suffering a hip fracture. Women who did not smoke only had a 6% increased risk when taking a PPI. The new study is just the latest in a series of independent and government research that has linked an increased risk of bone fractures to PPI medications like Dexilant.
The severity of the bone fracture depends on a variety of factors including the propensity to fall, visual acuity, response to falling and bone strength. Bone mass is the single most important factor in determining bone strength, and accounts for up to 80% of its variance. Fracture sites, on the other hand, are typically age related. Wrist fractures are common for people in their fifties, while those in their sixties are most susceptible to spine fractures. By the time an individual reaches their seventies, the hip becomes the most common site of osteoporotic fracture.
In May 2010, the FDA issued a safety announcement stating that it was revising the labels of PPI drugs. The warning alerted patients that this class of drugs may increase the risk of wrist, hip and spine fractures. In the press release, the administration advised users and their doctors to weigh the known benefits of these medications against the significant risks. The following statement illustrates the dangers associated with Dexilant and other PPI’s:
“Epidemiology studies suggest a possible increased risk of bone fractures with the use of proton pump inhibitors for one year or longer, or at high doses,” said Dr. Joyce Korvick, FDA’s Division of Gastroenterology Products deputy director for safety. “Because these products are used by a great number of people, it’s important for the public to be aware of this possible increased risk and, when prescribing proton pump inhibitors, health care professionals should consider whether a lower dose or shorter duration of therapy would adequately treat the patient’s condition.”
Side Effects of Dexilant
Proton pump inhibitor drugs like Dexilant may increase the risk of the following serious side effects:
- Acute interstitial nephritis (inflammation of the kidneys)
- Acute kidney injury
- Chronic kidney disease (CKD)
- Kidney failure (renal failure)
- Cardiac disorders
- Heart attack
- Bone fractures (hip fracture, wrist fracture, spine fracture)
- Broken bones
- Low magnesium levels (hypomagnesemia)
- Stomach cancer
- Gut infections
- Erectile dysfunction (ED) in men
- Severe allergic reactions
- And more
If You Are Taking Dexilant
Since heartburn is often confused with the first symptoms of a heart attack, seek immediate medical attention if you have chest pain or pain spreading to the arm or shoulder. You should not take Dexilant if you have a family history of liver disease or low levels of magnesium in your blood. Tell your doctor if you have osteoporosis or osteopenia (low bone mineral density). Dexilant is currently classified as a Pregnancy Category B medication, meaning that it is not expected to cause birth defects. Do not use Dexilant if you are breast feeding a baby, as the drug may pass into breast milk and could harm a nursing child.
PPI Kidney Injury Suits Centralized in New Jersey
August 4, 2017 – The U.S. Judicial Panel on Multidistrict Litigation (JPML) on Wednesday ordered that all federally-filed lawsuits involving kidney injuries from PPI heartburn drugs will be consolidated in the District of New Jersey for pretrial handling. The panel’s ruling marked an about-face from it’s previous opinion on the matter, having in February rejected a bid to create an MDL. The reason for the change was due to the litigation’s substantial increase in size since the initial ruling, and because 2 defendants who previously opposed centralization — AstraZeneca and Pfizer — are now in support of it, according to JPML.
Study Finds Increased Risk of Death with PPI Heartburn Medications
July 5, 2017 – Proton pump inhibitors have been linked to a 25% greater risk of death compared to patients who took H2 blockers, according to a study published Monday in BMJ. The study also found that PPI use was linked to a 15% increased death rate compared to patients who took another kind of acid suppressor other than H2 blockers, and that the death rate was 23% higher among PPI users compared to people who took no such medications.
PPIs Linked to Increased Risk of Pneumonia in Dementia Patients
April 5, 2017 – Dementia patients who take proton pump inhibitors have an 89% increased risk of developing pneumonia compared to dementia patients who don’t use the medications, according to a study published last month in the Journal of the American Geriatrics Society. Independent risk factors for pneumonia included age, male gender, underlying cerebrovascular disease, chronic pulmonary disease, congestive heart failure, diabetes mellitus, and antipsychotic use.
PPIs Linked to Increased Risk for Heart Failure, Death
March 23, 2017 – Proton pump inhibitor heartburn medicines have been linked to an increased risk for heart failure and death in patients with coronary artery disease (CAD), according to a recent study published in PLOS ONE. The researchers found that PPIs are commonly used to prevent complications in CAD patients treated with chronic antiplatelet therapy (aspirin, Plavix, Effient); however, when used in this capacity, proton pump inhibitors may increase the risk of adverse health consequences including pneumonia, micronutrient deficiencies, and osteoporosis-related fractures.
PPIs May Increase Risk of GI Infection, Study Finds
January 6, 2017 – People who take proton pump inhibitors may be at an increased risk for developing severe stomach infections, according to a study published Thursday in the British Journal of Clinical Pharmacology. The researchers found that among a cohort of 565,000 adults, patients who used PPIs had higher rates of infection with C. difficile and Campylobacter bacteria compared to those who didn’t take the medications. PPIs work by blocking stomach acid production, and the study’s authors suspect that this mechanism of action may change the balance of “good” and “bad” bacteria in the gut, leaving users vulnerable to gastrointestinal infection.
Study Links PPIs and Kidney Damage, End-Stage Renal Disease (ESRD)
“This is very important from an epidemiologic point of view and also from a clinical perspective,” said study author Ziyad Al-Aly, MD, of the Clinical Epidemiology Center, VA Saint Louis Health Care System. “We also show that risk increases with increased duration of exposure. The constellation of findings suggests a strong and intimate link between PPI use and untoward kidney outcomes.”
Plaintiffs Move to Consolidate PPI Kidney Damage Lawsuits
October 20, 2016 – Plaintiffs alleging kidney injuries (acute interstitial nephritis, chronic kidney disease and renal failure) from proton pump inhibitors have filed a motion seeking consolidation of the cases in the Middle District of Louisiana. To date, at least 15 such complaints have been filed in federal courts across the U.S. However, plaintiffs allege that hundreds or even thousands more suits will eventually be filed, warranting creation of the MDL.
Proton Pump Inhibitors Linked to Rhabdomyolysis
September 26, 2016 – A new case study has found that use of PPIs like Dexilant may increase the risk of rhabdomyolysis, a syndrome caused by the release of muscle fibers into the bloodstream. The study describes the case of a 45-year-old man who was hospitalized for persistent lower chest pain and treated with a single intravenous dose of Nexium (esomeprazole), after which he developed rhabdomyolysis. The findings were published in last month’s edition of the journal Medicine.
PPIs Linked to Brain Problems, Fluid Buildup
September 1, 2016 – Proton pump inhibitors like Dexilant may cause loss of brain function (hepatic encephalopathy or ‘HE’) and fluid buildup in the abdomen (ascites), according to a study published last month in Hepatology. The study’s authors found that 52% of patients used a PPI during clinical trials, and these patients had a 31% cumulative 1-year risk for HE. The researchers cautioned doctors against prescribing PPIs to patients with possible cirrhosis.
Study Finds Increased Risk of Cardiovascular Complications With PPI Heartburn Drugs
August 19, 2016 – Heart disease patients who take proton pump inhibitors like Dexilant face an increased risk for anemia, lower weight and a worsening metabolic profile, according to a recent study published in the International Journal of Cardiology. The researchers theorized that this could be partially due to the decreased use in this group of ACE-inhibitors (which reduce blood pressure) and statins (which reduce blood cholesterol). Patients should avoid using PPIs long-term, the study’s authors cautioned.
Do I have a Dexilant Lawsuit?
The Pharmaceutical Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Dexilant lawsuits. We are handling individual litigation nationwide and currently accepting new injury and death cases in all 50 states.
Free Confidential Case Evaluation: Again, if you were harmed by Dexilant side effects, you should contact our law firm immediately. You may be entitled to a settlement by filing a lawsuit and we can help.